Business Standard

After disappointing Q4, Glenmark gives a guidance of 15% revenue growth

Says it saw lower than estimated sales for its top selling anti-cholesterol drug Zetia

glenmark
Premium

Photo: Reuters

Aneesh Phadnis Mumbai
Glenmark has guided 12-15 per cent revenue growth in FY 18 after a disappointing fourth quarter result which led to 15 per cent fall in stock price in intra day trade on Friday.

The drug maker said it had seen lower than estimated sales of its top selling anti-cholesterol drug Zetia and was also impacted by price erosion in the US market.

At 12 pm, the stock was trading at Rs 782.75.

The company management said it plans to launch 10-15 products including 3-4 products in the US in FY 18 which will drive growth. Also, it said

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in